GERMANY – Bayer Consumer Health has launched a call through IN-PART’s Discover platform to find and partner with academic experts and research groups working on microbiome-targeting solutions for upper respiratory illnesses, nutrition and digestive health as well as topical delivery through the skin.
The campaign aims to accelerate Bayer’s “Partner with Us” initiative by expanding its global educational network and collaborating with cutting-edge microbiome research to bring new treatments to patients faster than ever before.
Bayer seeks to partner with academic teams to identify new agents for non-pharmaceutical consumer use; Next generation probiotic and biotic strains for targeted health benefits; and platform for effective manufacturing and distribution, as well as methodology or diagnostics to identify candidates who address unmet health needs through personalized products.
The skin microbiome market is set to touch a promising growth of US$1.9 billion from US$699.3 million during the forecast period of 2022 to 2029 with a CAGR of 13.68 percent according to Data Bridge Market Research analysis.
“Partnership is at the core of our innovation work at Bayer,” said Karen Hackney, Head of External Innovation and Partnerships at Bayer Consumer Health.
“By combining new ideas and expertise in emerging areas with our trusted brands and global scale, the partnership helps us deliver truly great self-care products to consumers.”
There are many opportunities for academic researchers to partner with Bayer Consumer Health through campaigns, including asset licensing and research collaborations, depending on the nature of the research project.
The skin microbiome market is set to touch a promising growth of US$1.9 billion from US$699.3 million during the forecast period of 2022 to 2029 with a CAGR of 13.68 percent according to Data Bridge Market Research analysis.
Factors driving the growth of the market owing to their ability to protect the skin from harmful organisms.
Other factors such as their ability to regulate the skin’s pH, make the skin essential nutrients and lipids, and make the skin healthier and more resilient skin microbiome market forward during the forecast period from 2022 to 2029.
The human body is home to more than 100 trillion microbes including bacteria, fungi, and viruses that live in communities called microbiomes all over the body.
These symbiotic microbes have evolved alongside human beings and are essential to our health and well-being, influencing everything from stimulating the immune system, to breaking down potentially toxic food compounds in the guts and synthesizing certain vitamins and amino acids.
More information about Bayer Consumer Health’s technical requirements and the process for submitting proposals or existing projects can be found on the Discover IN-PART platform.
Discover is a bespoke scouting platform used by innovation and R&D teams in industry to identify new academic partners at more than 2,400 institutions and is free for researchers and commercialization teams to use.
Submissions should contain only non-confidential information and summarize the project in approximately 300 words, Bayer said. The submission deadline is August 30, 2022, at 10:59 PM GMT.
Katie Siddle, head of industry partnerships at In-Part said: “The microbiome is very important for many regulatory processes in the body, and the solutions emerging from this campaign will have a huge impact on patients.
The Bayer Consumer Health initiative is a great way for academic researchers to forge new relationships with the global leader in consumer health and pharmaceuticals.”
In other news, Sequential Skin has been awarded approximately half a million euros as part of the Innovate UK SMART Grant to fund an initiative that advances understanding of the skin microbiome.
The 465k Euros (US$475k) grant is to fund the project over 18 months to research genetic skin microbiome inputs, during disease progression, that may lead to helping to identify patients in the future.
Sequential Skin Ltd. a London-based skin genomic startup, will use their novel testing kits launched earlier this year.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE